Seer (NASDAQ:SEER) Releases Earnings Results, Misses Estimates By $0.04 EPS

Seer (NASDAQ:SEER) announced its earnings results on Tuesday. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.04), FiscalAI reports. Seer had a negative net margin of 464.78% and a negative return on equity of 26.58%. The business had revenue of $3.10 million during the quarter, compared to analyst estimates of $3.55 million.

Here are the key takeaways from Seer’s conference call:

• Revenue remained under pressure, with second-quarter revenue of $3.1 million versus $4.1 million a year earlier, due to weak academic and government funding and longer sales cycles. The company posted a $16.9 million net loss.
• Management reaffirmed full-year 2026 revenue guidance of $16 million to $18 million, citing stronger customer discussions, increased consumable pull-through, new commercial leadership, and anticipated population-scale study opportunities in the second half.
• Seer reported more than 95 publications, preprints, and reviews supporting the Proteograph platform, while independent studies highlighted its depth, reproducibility, and ability to identify proteins and genetic associations missed by competing assays.
• The company ended the quarter with $209.5 million in cash and investments, believes it has sufficient capital to reach cash-flow breakeven, and has repurchased approximately 13.4 million shares, reducing net shares outstanding by about 15%.
• Seer completed the first 10,000 samples of its PRECISE-SG100K population study and plans to present preliminary data at HUPO in September, while continuing discussions with potential large-scale cohort partners. Management views these results as a potential catalyst for larger buyback commitments and broader adoption.

Seer Stock Performance

Shares of Seer stock opened at $2.16 on Wednesday. The company has a market cap of $118.76 million, a P/E ratio of -1.74 and a beta of 1.56. Seer has a one year low of $1.55 and a one year high of $2.41. The firm has a fifty day moving average of $1.95 and a two-hundred day moving average of $1.88.

Analyst Upgrades and Downgrades

A number of research firms have commented on SEER. Canaccord Genuity Group began coverage on shares of Seer in a research note on Monday, May 4th. They issued a “buy” rating and a $4.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a research note on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Seer has a consensus rating of “Buy” and an average price target of $4.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Corient Private Wealth LLC purchased a new position in Seer during the fourth quarter worth about $116,000. Quadrature Capital Ltd acquired a new position in Seer during the 4th quarter worth approximately $101,000. Barclays PLC lifted its holdings in shares of Seer by 685.0% in the 4th quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after buying an additional 52,982 shares during the period. Marshall Wace LLP purchased a new stake in shares of Seer in the fourth quarter valued at approximately $85,000. Finally, Dimensional Fund Advisors LP raised its position in Seer by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 235,485 shares of the company’s stock worth $431,000 after acquiring an additional 6,304 shares in the last quarter. 75.20% of the stock is currently owned by institutional investors and hedge funds.

Seer Company Profile

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.